About Us

Leading the way to a potential new standard of care for gastrointestinal diseases

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI diseases. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. We plan to initiate Phase 3 clinical trials for the treatment of erosive GERD and the treatment of H. pylori infection. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Executive Leadership Team

Tadataka (Tachi) Yamada, M.D., serves as a Venture Partner with Frazier Healthcare Partners and serves as a Director of Agilent Technologies, CSL, and a number of private life sciences companies. As a member of the Frazier Life Sciences team, Dr. Yamada focuses on both creating companies as well as providing strategic guidance to existing portfolio companies. Dr. Yamada was previously Chief Medical Officer and Chief Scientific Officer at Takeda Pharmaceuticals and a member of the company’s Board of Directors. In this role, Dr. Yamada was responsible for all of Takeda’s research and development activities and a budget of nearly $4 billion. Prior to Takeda, Dr. Yamada was President of the Bill & Melinda Gates Foundation Global Health Program in Seattle, where he oversaw over $9 billion in grants for applying technologies to address major health challenges of the developing world. Before joining the Gates Foundation, he was Chairman of Research and Development at GlaxoSmithKline and member of the Board of Directors. Dr. Yamada was the Chief of the Division of Gastroenterology and the Chair of the Department of Internal Medicine at the University of Michigan in Ann Arbor. Dr. Yamada earned his M.D. from New York University School of Medicine and a B.A. in History from Stanford University. He has authored more 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology.

David Socks is a Venture Partner with Frazier Healthcare Partners, where he focuses on company creation. In this capacity, he co-founded Outpost Medicine, Passage Bio, Recida Therapeutics and Scout Bio. Mr. Socks was Chief Executive Officer of Outpost and Scout, and he currently serves as Executive Chairman of Recida and as a Board member of Outpost. Prior to joining Frazier, he co-founded Incline Therapeutics and served as the company’s President and Chief Operating Officer until its sale to The Medicines Company for up to $390 million. Previously, he was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Cadence (acquired by Mallinckrodt for $1.3 billion), Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). At Cadence, Mr. Socks served as Senior Vice President of corporate development and strategy. He has also worked in private equity and management consulting. Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.

Azmi Nabulsi, M.D., is the former Deputy Chief Medical Officer, Chief Scientific Officer and Head of Global Development at Takeda Pharmaceuticals. In these roles, he led all global research and development, medical, regulatory, operations and data analytics functions. In addition, he led research and development portfolio management strategy and planning, focusing on enhancing the company’s pipeline and productivity. During his 14-year career at Takeda U.S. and Japan, Dr. Nabulsi oversaw global drug development for both early and late stage product candidates, and he was responsible for bringing the majority of Takeda’s 21 new drugs in multiple therapeutic areas and countries to market. He was also responsible for the design and execution of the company’s major research and development transformation, utilizing industry leading approaches to drive innovation. Dr. Nabulsi has led or directed partnerships and alliances in gastroenterology, oncology, immunology, cardiovascular medicine and metabolism. Prior to Takeda, he held leadership positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures. Dr. Nabulsi has an M.D. from Ain-Shams University in Cairo and a M.P.H. from the University of Minnesota.

Aditya Kohli, Ph.D., is a Vice President with Frazier Healthcare Partners, where he focuses on company creation. In addition to Phathom, he co-founded Scout Bio, Passage Bio and Recida Therapeutics and serves on the Board of Scout Bio. Prior to Frazier, Dr. Kohli was a management consultant with McKinsey & Company, where he led engagements advising global biopharmaceutical companies on business development, research and development, and marketing and sales strategy. Dr. Kohli received his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and holds B.S. and M.Eng. degrees in biological engineering from MIT.

Roger Ulrich, Ph.D., is a Senior Advisor on the Frazier Healthcare Partners Life Sciences team, and brings several decades of both leadership and operational experience within the pharmaceutical industry. Dr. Ulrich was Chief Scientific Officer and a member of the founding Board of Directors of Acerta Pharma through its majority-share acquisition by AstraZeneca. He was previously Co-founder and Chief Development Officer with Calistoga Pharmaceuticals. Calistoga was acquired by Gilead Sciences, and Dr. Ulrich continued with Gilead to help with the Calistoga integration and complete the development of its lead product candidate. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories, where he helped guide the Merck integration of Seattle-based Rosetta Inpharmatics. He was also Director of Drug Safety Evaluation at Abbott Laboratories, and was Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his career in the pharmaceutical industry, he held research positions at West Virginia and Michigan State Universities, and at Argonne National Laboratories. He currently serves on the Boards of Acerta Pharma, Remedy Pharmaceuticals, and Aminex, and serves as a scientific advisor to several small companies. Dr. Ulrich received his Ph.D. in cellular and molecular biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He holds several patents, has authored more than 120 publications and is a Fellow of the Academy of Toxicological Sciences.

Tom Harris is the former Senior Vice President and Head of Global Regulatory Affairs at Takeda, where he was responsible for all global regulatory matters at Takeda while overseeing regulatory personnel in US, Europe, Japan and Singapore from 2012 to 2019. Previously, Mr. Harris held multiple positions of increasing responsibility over 19 years within Abbott International’s Global Regulatory Affairs function. He held the position as the Global Regulatory Head for the Abbott Immunology franchise, which included oversight and responsibility of the worldwide submissions of HUMIRA® for rheumatology, gastroenterology and dermatology indications. He also served as the Global Project Head leading Humira Global Project Teams in dermatology and new indications in spondyloarthropathies and uveitis. Before joining industry, Mr. Harris was a staff pharmacist at Good Shepherd Hospital in Barrington, IL. Mr. Harris earned a B.S. in Pharmacy from the University of Iowa College of Pharmacy.

Board of Directors

Tadataka (Tachi) Yamada, M.D., serves as a Venture Partner with Frazier Healthcare Partners and serves as a Director of Agilent Technologies, CSL, and a number of private life sciences companies. As a member of the Frazier Life Sciences team, Dr. Yamada focuses on both creating companies as well as providing strategic guidance to existing portfolio companies. Dr. Yamada was previously Chief Medical Officer and Chief Scientific Officer at Takeda Pharmaceuticals and a member of the company’s Board of Directors. In this role, Dr. Yamada was responsible for all of Takeda’s research and development activities and a budget of nearly $4 billion. Prior to Takeda, Dr. Yamada was President of the Bill & Melinda Gates Foundation Global Health Program in Seattle, where he oversaw over $9 billion in grants for applying technologies to address major health challenges of the developing world. Before joining the Gates Foundation, he was Chairman of Research and Development at GlaxoSmithKline and member of the Board of Directors. Dr. Yamada was the Chief of the Division of Gastroenterology and the Chair of the Department of Internal Medicine at the University of Michigan in Ann Arbor. Dr. Yamada earned his M.D. from New York University School of Medicine and a B.A. in History from Stanford University. He has authored more 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology.

David Socks is a Venture Partner with Frazier Healthcare Partners, where he focuses on company creation. In this capacity, he co-founded Outpost Medicine, Passage Bio, Recida Therapeutics and Scout Bio. Mr. Socks was Chief Executive Officer of Outpost and Scout, and he currently serves as Executive Chairman of Recida and as a Board member of Outpost. Prior to joining Frazier, he co-founded Incline Therapeutics and served as the company’s President and Chief Operating Officer until its sale to The Medicines Company for up to $390 million. Previously, he was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Cadence (acquired by Mallinckrodt for $1.3 billion), Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). At Cadence, Mr. Socks served as Senior Vice President of corporate development and strategy. He has also worked in private equity and management consulting. Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.

Terrie Curran is the President, Global Inflammation and Immunology (I&I) Franchise and a member of the Executive Committee at Celgene Corporation and has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA®. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co. She currently serves on the Board of Myovant Sciences and previously served on the board of H. Lundbeck A/S. Ms. Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. Throughout his 14 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead), Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), Cotherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the Boards of Allena Pharmaceuticals, Alpine Immune Sciences, AnaptysBio, Aptinyx, and Amunix Therapeutics. He is also a Board observer for Alcresta Therapeutics and Sojournix. Prior to joining Frazier, Dr. Topper served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston and is board certified in both disciplines. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 and 2016, Jamie was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.

Jon Edwards is a Partner at Medicxi, a leading international investment firm focused on life sciences. Prior to joining Medicxi, Dr. Edwards worked at Index Ventures in Geneva as an Associate for two years. Before that, he worked as a life science strategy consultant at ClearView Healthcare Partners in Boston. He currently serves on the Board of Directors of Palladio Biosciences, Xenikos, Z-Factor, UltraHuman, Breakpoint Therapeutics, and Sydnexis. Dr. Edwards was also previously a Director of Impact Biosciences. He obtained his Ph.D. in biochemistry and biophysics from UNC Chapel Hill and conducted postdoctoral research at MIT.

Heidi Kunz retired as the Executive Vice President and Chief Financial Officer of Blue Shield of California. She previously served as the Executive Vice President and Chief Financial Officer of Gap, Inc., Chief Financial Officer of ITT Industries, Inc., and Treasurer of General Motors. Ms. Kunz holds a B.S. from Georgetown University and an M.B.A. from Columbia University. She also serves on the board of Agilent Technologies and Avanos Medical.

Mike Cola currently serves as President, Chief Executive Officer, and director of Aevi Genomic Medicine. Prior to joining Aevi, he served as President, Specialty Pharmaceuticals at Shire plc. Previously, Mr. Cola served as President of the life sciences group for Safeguard Scientifics, where he also served as Chairman and Chief Executive Officer of Clarient and Chairman of Laureate Pharma. In addition, Mr. Cola has held senior positions at AstraMerck and AstraZeneca where he played a key role in the development and commercialization of both PRILOSEC® and NEXIUM®. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the Board of Directors at Sage Therapeutics and Vanda Pharmaceuticals.

Chris Slavinsky serves as Vice President, Takeda Center for External Innovation and Head, Gastroenterology Business Development, Externalization and Special Projects. Previously, Chris served in a number of capacities at Pfizer, including as Chief Counsel of several Pfizer business segments. Mr. Slavinsky received a J.D. from the Washington University in St. Louis School of Law, an M.S. in biochemistry and molecular biology from Thomas Jefferson University, and a B.S. in biochemistry from the State University of New York at Stony Brook. He also serves on the Board of Directors at ARTham Therapeutics.